MYC and medulloblastoma: In the c‐myc‐amplified Non‐WNT/Non‐SHH medulloblastoma lines MEB‐Med‐8A and D283 Med, Axitinib reduces viable cell number in a dose‐dependent manner starting at the lowest concentration of 0.5 μM, while in the SHH‐TP53‐mutated cell line Daoy, a significant decrease was only observed at 2 μM, the highest concentration applied.